LDK378
≥99%
- Product Code: 202264
CAS:
1032900-25-6
| Molecular Weight: | 558.14 g./mol | Molecular Formula: | C₂₈H₃₆ClN₅O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | Room temperature, dry, sealed |
Product Description:
Used in the treatment of ALK-positive non-small cell lung cancer, LDK378 (also known as ceritinib) is a potent inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. It is specifically designed to target tumors that have developed resistance to earlier ALK inhibitors, making it effective in patients who have progressed on prior therapies. The compound also shows activity against insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1 kinases, broadening its potential therapeutic use. Administered orally, it achieves high concentrations in the central nervous system, offering clinical benefit in patients with brain metastases. Its development represents a significant advancement in personalized medicine for lung cancer patients with specific genetic alterations.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | ฿300.00 |
+
-
|
| 25mg | 10-20 days | ฿680.00 |
+
-
|
| 100mg | 10-20 days | ฿1,300.00 |
+
-
|
| 250mg | 10-20 days | ฿1,900.00 |
+
-
|
| 1g | 10-20 days | ฿5,700.00 |
+
-
|
| 5g | 10-20 days | ฿22,960.00 |
+
-
|
LDK378
Used in the treatment of ALK-positive non-small cell lung cancer, LDK378 (also known as ceritinib) is a potent inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. It is specifically designed to target tumors that have developed resistance to earlier ALK inhibitors, making it effective in patients who have progressed on prior therapies. The compound also shows activity against insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1 kinases, broadening its potential therapeutic use. Administered orally, it achieves high concentrations in the central nervous system, offering clinical benefit in patients with brain metastases. Its development represents a significant advancement in personalized medicine for lung cancer patients with specific genetic alterations.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :